成人首次加强接种FSME-IMMUN 0.5mL后10年蜱传脑炎病毒抗体血清持续性与第二剂加强接种应答
该研究在315名健康成人中评估首次加强接种FSME-IMMUN后2-5年及7-10年的蜱传脑炎病毒抗体血清持续性,结果显示首次加强接种后10年84.9%的受试者仍为血清阳性,50岁以下受试者血清阳性率更高(88.6%),第二剂加强接种时机取决于年度随访血清学观察到的抗体水平。
要点
- 首次加强接种FSME-IMMUN后10年,成人受试者血清阳性率为84.9%。
- 50岁以下受试者血清阳性率更高,为88.6%。
- 第二剂加强接种时机取决于年度随访血清学观察到的TBE抗体水平。
核心结论
- 成人受试者在完成3剂基础免疫和首次加强接种FSME-IMMUN后10年,84.9%仍为血清阳性。
- 50岁以下受试者的血清阳性率更高,为88.6%。
研究设计与样本
- 在315名健康成人同一研究人群中开展的两项随访研究。
- 在既往研究中接种FSME-IMMUN首次加强疫苗后第2-5年及第7-10年每年采血评估TBE病毒抗体血清持续性。
- 第二剂加强接种时机取决于每年随访血清学观察到的血清TBE抗体水平。
主要发现
- 成人受试者在3剂基础免疫和首次加强接种FSME-IMMUN后10年血清阳性率为84.9%。
- 50岁以下受试者血清阳性率为88.6%,高于总体人群的84.9%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tick-borne encephalitis (TBE) is a viral disease that can have a severe acute clinical course and considerable long-term morbidity. As there is no causal treatment currently available for TBE, vaccination is the only way to combat the disease in endemic areas. The studies presented here were conducted to obtain prospective long-term TBE serum antibody persistence data of subjects up to 10years after the first booster with FSME-IMMUN. This report presents the results of 2 follow-up studies in the same study population of 315 healthy adults. Blood was drawn to assess the seropersistence of TBE virus antibodies yearly, from 2-5 and 7-10years after the first booster vaccination with FSME-IMMUN administered during a previous study. The timing of the second booster vaccination was dependent on the level of serum TBE antibodies observed during yearly follow-up serology observations. The current follow up showed that adult recipients were 84.9% seropositive 10years after a 3 dose primary series and the first booster vaccination of FSME-IMMUN. Seropositivity rates were even higher (88.6%) in subjects below 50years of age. ClinicalTrials.gov Identifier: NCT00503529. ClinicalTrials.gov Identifier: NCT01582698.
引用
- Konior R, Brzostek J, Poellabauer EM, et al. Seropersistence of TBE virus antibodies 10 years after first booster vaccination and response to a second booster vaccination with FSME-IMMUN 0.5mL in adults. Vaccine. 2017. PMID: 28545923. doi:10.1016/j.vaccine.2017.03.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。